期刊文献+

用室间质量评价西格玛图评价脂类项目不同检测系统的质量水平 被引量:3

Assessing Quality of Different Measuring Systems on the Sigma Scale from External Quality Assessment
下载PDF
导出
摘要 目的探讨用室间质量评价西格玛图评价脂类正确度验证不同检测系统的质量水平。方法收集参加2014年第1次全国脂类正确度验证室问质量评价获得的数据,计算Bias%和CV%,可构建一种“室间质量评价西格玛图”,以评价不同检测系统的不精密度和偏倚,并以西格玛水平表示检测系统的质量。结果剔除异常值和小于5家实验室的检测系统数据,分别以项目要求的TEa%规范进行分析。血清总胆固醇201411和201412样品的平均偏倚分剐为2.10%和2.17%,平均CV%为3.17%和3.21%,加权西格玛分别为2.53和2.50;血清总三酰甘油201411和201412样品的加权西格玛为4.16和5.10;高密度脂蛋白胆固醇201411和201412样品的加权西格玛为4.53和4.48;低密度脂蛋白胆固醇201411和201412样品加权西格玛为4.98和2.67。从西格玛图中可直观地看到不同检测系统的西格玛水平。结论用西格玛水平评估质量可提供实现预期用途要求的分析性能证据,有助于实验室检验分析质量中的识别和优化改进。 Objective To discuss the application of Six Sigma concepts and metrics, which can provide an objective assessment of current analytical quality of different examination procedures. Methods The data were collected from laboratories partici- pated in anlipid survey in 2014. A "Sigma External Quality Assessment Chart" could be constructed for data obtained from external quality assessment surveys to evaluate the observed imprecision and bias of method subgroups and determine quality on the Sigma scale. Results Abnormal values and the system whose quantity was less than 5 were excluded. When evaluated against the NCCL requirement of an allowable total error,the weighted average were 2.53 Sigma for 201411 sample of totai cholesterol ( average bias 2.10%, CV 3.17% ) and 2.50 Sigma for 201412 ( average bias 2.17%, CV 3.210%), respietively. The weighted average were 4.16 Sigma for 201411 sample of total glycerol (average bias 3. 98% ,CV6.38%) and 5.10 Sig ma for 201412 (average bias 3.65%, CV 4.71% ), respictively. The weighted average were 4.53 Sigma for 201411 sample of HDL-C (average bias 2.65% ,CV 6.94%) and 4.48 Sigma for 201412(average bias 1.91% ,CV 6.74%) , respictively. The weighted average were 4.98 Sigma for 201411 sample of LDL-C (average bias 2.99%,CV 5.98%) and 2.67 Sigma for 201412(average bias 14. 57% ,CV5. 93%),respictively. The sigma scale can be seen from the Sigma External Quality Assessment Chart. Conclusion Assessment of quality on the Sigma scale provides evidence of the analytical performance that is being achieved relative to requirement for intended use and should be useful for identifying and prioritizing improvements that are needed in the analytical quality of laboratory examinations.
出处 《现代检验医学杂志》 CAS 2015年第6期80-83,共4页 Journal of Modern Laboratory Medicine
基金 北京市自然科学基金(基金编号:7143182),北京医院课题资助(BJ-2015025).
关键词 室间质量评价 偏倚 不精密度 西格玛质量 external quality assessment bias imprecision sigma quality
  • 相关文献

参考文献6

  • 1Plebani M. The CCI.M contribution to improvements in qua!.ity and patient safety[J]. C[in Chem Lab Med, 2013,51(1) :39-46.
  • 2Westgard JO,Westgard SA. The quality of laboratory testing today: an assessment of sigma metrics for an- alytical quality using performance data from proficien cy testing surveys and the CLIA criteria for accepta- ble performance[J]. Am J Clin Pathol, 2006,125 (3) : 343-354.
  • 3Westgard JO,Westgard SA. Basic quality manageme- nt systems: essentials for quality management in the medical laboratory[M]. Madison WI: Westgard QC, Ine, 2014 : 234-235.
  • 4张丽,陈曦.血清高敏C反应蛋白与心血管病关系的研究进展[J].国际检验医学杂志,2006,27(5):435-436. 被引量:28
  • 5Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: as- sessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trifil [J]. Am J Cardial,2000,86(12A) :19-22.
  • 6Magnusson B, Ellison SL. Treatment of uncorrected measurement bias in uncertainty estimation for chemi- cal measurements [J ]. Anal Bioanal Chem, 2008,390 (1):201-213.

二级参考文献14

  • 1Guijarro C. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 2001, 104(22): E127.
  • 2Hoffmann JA, Kafatos FC, Janeway CA, et al. Phylogenetie perspectives in innate immunity. Science, 1999, 284 (5418): 1313-1318.
  • 3de-Wint or RJ, Bholasingh R, Lijmer JC, et al.Independent prognostic value of C reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction.Cardiovasc Res, 1999, 42(1): 240-245.
  • 4Uchara K, Nomura M, Ozaki Y, et al. High-sensitivity C-reactive protein and left ventrieular remodeling in patients with acute myocardial infarction. Heart Vessels, 2003, 18(2):67-74.
  • 511 Bautista I.E, Lopez-Jaramillo P, Vera LM, et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens, 2001, 19(5): 857-861.
  • 6Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk : rationale for screening and primary prevention. Am J Cardiol,2003, 92(4B): 17K-22K.
  • 7Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive prorein and low density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med, 2002, 347(20):1557-1565.
  • 8Tsunoda K, Arita M, Yukawa M, et al. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type2 diabetic patients. J Diabetes Complications, 2005, 19(3):123-127.
  • 9Nakanishi N, Shiraishi T, Wada M. Association between C-reactive protein and insulin resistance in a Japanese population: the Minoh Study. Intern Med, 2005, 44(6): 542-547.
  • 10Kimberly MM, Vesper HW, Caudill SP, et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. Clin Chem, 2003, 49(4): 611-616.

共引文献27

同被引文献19

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部